Update on romiplostim and eltrombopag indirect comparison by Cooper, K. et al.
This is a repository copy of Update on romiplostim and eltrombopag indirect comparison.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/97346/
Version: Accepted Version
Article:
Cooper, K., Matcham, J., Helme, K. et al. (1 more author) (2014) Update on romiplostim 
and eltrombopag indirect comparison. International Journal of Technology Assessment in 
Health Care, 30 (1). pp. 129-130. ISSN 0266-4623 
https://doi.org/10.1017/S0266462313000767
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright 
exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy 
solely for the purpose of non-commercial research or private study within the limits of fair dealing. The 
publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White 
Rose Research Online record for this item. Where records identify the publisher as the copyright holder, 
users can verify any specific terms of use on the publisher’s website. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
 hWdKE “ZKD/W>K^d/DE>dZKDKW'&KZ/DDhEd,ZKDKzdKWE/ PDd,K^
&KZ/E/ZdKDWZ/^KE ? 
Katy Cooper, University of Sheffield, UK 
James Matcham, Amgen Ltd, Cambridge, UK 
Kawitha Helme, Amgen Ltd, Uxbridge, UK 
Ron Akehurst, University of Sheffield, UK 
 
Dear Dr Mäkelä,  
/ŶŽƵƌĂƌƚŝĐůĞ ?ZŽŵŝƉůŽƐƚŝŵĂŶĚĞůƚƌŽŵďŽƉĂŐĨŽƌŝŵŵƵŶĞƚŚƌŽŵďŽĐǇƚŽƉĞŶŝĂ ?ŵĞƚŚŽĚƐĨŽƌŝŶĚŝƌĞĐƚ
ĐŽŵƉĂƌŝƐŽŶ ?ƉƵďůŝƐŚĞĚŝŶƚŚŝƐũŽƵƌŶĂů ?1], we presented an indirect comparison of the effectiveness 
of eltrombopag and romiplostim in raising platelet counts in patients with immune 
thrombocytopenia (ITP). Indirect comparison analyses are recommended by the National Institute 
for Health and Care Excellence (NICE) in cases where randomized head-to-head studies do not exist, 
and were used by NICE in their guidance for the eltrombopag Single Technology Appraisal 
submission [2].  
Following publication of our paper, updated data from the eltrombopag RAISE study were included 
in the evidence package to support the NICE final guidance regarding eltrombopag for the treatment 
of ITP [2,3]. These updated data included 14 additional patients receiving eltrombopag and 1 
additional patient receiving placebo assessed as having an overall platelet response, and 6 additional 
eltrombopag patients and no additional placebo patients assessed as having a durable platelet 
response (Table 1). We would like to describe the relevance of our original analyses in light of these 
new data, such that readers of International Journal of Technology Assessment in Health Care are 
aware of the full range of evidence available for informing health policy decisions on the use of 
eltrombopag and romiplostim. 
Several alternative methods are available for conducting an indirect treatment comparison. Our 
original article presented analyses using five methods, incorporating either a Bayesian or Bucher 
approach, and in each case the results indicated that romiplostim significantly improves overall 
platelet response compared with eltrombopag. We consider the Bayesian method to be a more 
robust approach than the Bucher method, since the Bayesian method includes all data in a single 
model that accounts for the heterogeneity between studies and preserves the within-trial 
randomization. The NICE Evidence Review Group (ERG) also considered the Bayesian analysis to be 
most appropriate, and used this approach in their review of the NICE eltrombopag submission [4]. 
Including the new eltrombopag response data, and using the same Bayesian methodology as 
previously used by us, the ERG found that the results remained consistent with our original analysis 
(Table 1): the overall platelet response was significantly higher in patients receiving romiplostim 
than in those receiving eltrombopag (odds ratio 0.15; 95% CI 0.02, 0.84), assuming medium 
heterogeneity. Also consistent with our original analysis, the ERG found that while the point 
estimate favoured romiplostim, there was no statistically significant difference in durable response 
between eltrombopag and romiplostim (odds ratio 0.20; 95% CI 0.01, 2.13).  
Results from indirect treatment comparisons between eltrombopag and romiplostim should be 
interpreted with caution due to heterogeneity between the study designs, patient populations, and 
 response definitions. Nonetheless, in the absence of head-to-head studies these analyses provide 
important evidence on the relative efficacy of the two currently available thrombopoietin-mimetics 
in patients with ITP. Using the same Bayesian approach as in our original paper, an independent 
research group on behalf of NICE (the ERG) have used updated evidence to demonstrate that the 
overall platelet response remains statistically significantly greater with romiplostim than with 
eltrombopag. 
 
Table 1: Comparison of platelet response rates between eltrombopag and romiplostim using 
updated data from the RAISE study. Odds ratios were calculated using Bayesian methodology [1,4]. 
 Eltrombopag trial data Romiplostim trial data Eltrombopag vs 
romiplostim 
OR (95% CI)  Eltrombopag Placebo Romiplostim Placebo 
Original data      
   Overall response 77/135 
(57%) 
7/62 
(11%) 
69/83 
(83%) 
3/42 
(7%) 
0.11 (0.02, 0.66) 
[Reference 1] 
      
   Durable response 57/135 
(42%) 
4/62 
(6%) 
41/83 
(49%) 
1/42 
(2%) 
0.15 (0.01, 1.88) 
[Reference 1] 
Updated data      
      
   Overall response 91/135 
(67%) 
8/62 
(13%) 
69/83 
(83%) 
3/42 
(7%) 
0.15 (0.02, 0.84) 
[Reference 4] 
      
   Durable response 63/135 
(47%) 
4/62 
(6%) 
41/83 
(49%) 
1/42 
(2%) 
0.20 (0.01, 2.13) 
[Reference 4] 
Response definitions in the romiplostim trials: overall platelet response was the percentage of patients with a 
platelet count  50 ǘ 109/L for at least 4 weeks during the trial, excluding responses within 8 weeks after 
rescue medications; durable platelet response was defined for romiplostim as the percentage of patients with 
platelet count  50 ǘ 109/L on at least 6 of the last 8 weeks of treatment, with no rescue medications at any 
time during the trial [1]. Response definitions in the eltrombopag trials: overall platelet response was a durable 
or transient response; transient response was platelets 50-400 ǘ 109 ?>ĨŽƌA? ?ĐŽŶƐĞĐƵƚŝǀĞǁĞĞŬƐĚƵƌŝŶŐ
treatment including all data up to time of withdrawal for patients who prematurely withdrew, excluding 
responses during rescue treatment and up to the time platelet counts fell below 50ǘ 109/L after cessation of 
rescue treatment; durable platelet response was platelets 50-400 ǘ 109/L for at least 6 of the last 8 weeks of 
treatment, excluding premature withdrawals and patients using rescue therapy at any time on treatment [3].  
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